Early immunotherapy in MS reduces the risk of later disability. the secondary progressive course is delayed, according to a study with virtual placebo

Tedeholm, H.; Skoog, B.; Hillert, J.; Runmarker, B.ör.; Stawiarz, L.; Oluf, A.

Lakartidningen 104(22): 1684-1688

2007


ISSN/ISBN: 0023-7205
PMID: 17601317
Document Number: 608220

Document emailed within 1 workday
Secure & encrypted payments